GlassScriptPhysician profile
William C Penley
NPI 1194743914
$1,425.22
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,028 · 2020: $303 · 2021: $11.92 · 2022: $37.12 · 2023: $16.56 · 2024: $28.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $45.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $45.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $275.43 | 2019-2024 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $93.04 | 2019-2020 | |
| Tesaro, INC. | $88.79 | 2019 | |
| Amgen INC. | $77.66 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $68.71 | 2019 | |
| Genzyme Corporation | $58.82 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $58.09 | 2019-2020 | |
| Taiho Oncology, INC. | $49.44 | 2019 | |
| Incyte Corporation | $48.97 | 2019-2022 | |
| Puma Biotechnology, INC. | $45.27 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $44.61 | 2019 | |
| Astellas Pharma US INC | $44.18 | 2019 | |
| Clovis Oncology, INC. | $43.63 | 2019-2020 | |
| Daiichi Sankyo INC. | $38.25 | 2019-2020 | |
| Blueprint Medicines Corporation | $34.98 | 2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $34.70 | 2019-2020 | |
| Lilly USA, LLC | $26.01 | 2019 | |
| Janssen Biotech, INC. | $25.15 | 2019-2020 | |
| Gilead Sciences, INC. | $24.64 | 2019-2021 | |
| Celgene Corporation | $21.86 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.42 | 2019 | |
| Biocompatibles, INC. | $19.75 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $17.22 | 2019 | |
| Morphosys, US INC. | $16.56 | 2023 | Monjuvi |
| Mylan Institutional INC. | $15.62 | 2020 | |
| Genentech USA, INC. | $15.15 | 2019 | |
| Beigene USA, INC. | $14.22 | 2020 | |
| Pfizer INC. | $14.01 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $13.89 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.89 | 2019 | |
| Exelixis INC. | $13.12 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.82 | 2019 | |
| Verastem, INC. | $12.47 | 2019 | |
| Dova Pharmaceuticals | $11.94 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Penley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.